Ann Daly
Ann Daly
Professor of Pharmacogenetics, Newcastle University
Verified email at ncl.ac.uk - Homepage
Title
Cited by
Cited by
Year
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl, J Zhang, Y Lin, J Lamba, M Assem, J Schuetz, PB Watkins, ...
Nature genetics 27 (4), 383-391, 2001
22682001
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
GP Aithal, CP Day, PJL Kesteven, AK Daly
The Lancet 353 (9154), 717-719, 1999
15411999
Estimation of the warfarin dose with clinical and pharmacogenetic data
International Warfarin Pharmacogenetics Consortium
New England Journal of Medicine 360 (8), 753-764, 2009
14812009
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
EA Sconce, TI Khan, HA Wynne, P Avery, L Monkhouse, BP King, P Wood, ...
Blood 106 (7), 2329-2333, 2005
11352005
Metabolic gene polymorphism frequencies in control populations
S Garte, L Gaspari, AK Alexandrie, C Ambrosone, H Autrup, JL Autrup, ...
Cancer Epidemiology and Prevention Biomarkers 10 (12), 1239-1248, 2001
10192001
HLA-B* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ...
Nature genetics 41 (7), 816-819, 2009
9052009
A randomized trial of genotype-guided dosing of warfarin
M Pirmohamed, G Burnside, N Eriksson, AL Jorgensen, CH Toh, ...
N Engl J Med 369, 2294-2303, 2013
7252013
Case definition and phenotype standardization in drug‐induced liver injury
GP Aithal, PB Watkins, RJ Andrade, D Larrey, M Molokhia, H Takikawa, ...
Clinical Pharmacology & Therapeutics 89 (6), 806-815, 2011
6152011
Nomenclature for human CYP2D6 alleles.
AK Daly, J Brockmöller, F Broly, M Eichelbaum, WE Evans, FJ Gonzalez, ...
Pharmacogenetics 6 (3), 193-201, 1996
5351996
Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease
L Valenti, A Al‐Serri, AK Daly, E Galmozzi, R Rametta, P Dongiovanni, ...
Hepatology 51 (4), 1209-1217, 2010
4792010
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics
M Niemi, JT Backman, LI Kajosaari, JB Leathart, M Neuvonen, AK Daly, ...
Clinical Pharmacology & Therapeutics 77 (6), 468-478, 2005
3792005
Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis
J Grove, AK Daly, MF Bassendine, CP Day
Hepatology 26 (1), 143-146, 1997
3661997
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
YL Liu, HL Reeves, AD Burt, D Tiniakos, S McPherson, JBS Leathart, ...
Nature communications 5 (1), 1-6, 2014
3492014
The role of individual human cytochrpmes P450 in drug metabolism and clinical response
S Cholerton, AK Daly, JR Idle
Trends in pharmacological sciences 13, 434-439, 1992
3461992
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles
MI Lucena, M Molokhia, Y Shen, TJ Urban, GP Aithal, RJ Andrade, ...
Gastroenterology 141 (1), 338-347, 2011
3422011
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants
J Zhang, P Kuehl, ED Green, JW Touchman, PB Watkins, A Daly, SD Hall, ...
Pharmacogenetics and Genomics 11 (7), 555-572, 2001
3402001
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations
JK Lamba, YS Lin, K Thummel, A Daly, PB Watkins, S Strom, J Zhang, ...
Pharmacogenetics and Genomics 12 (2), 121-132, 2002
3362002
Meta-and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk
S Benhamou, WJ Lee, AK Alexandrie, P Boffetta, C Bouchardy, ...
Carcinogenesis 23 (8), 1343-1350, 2002
3342002
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12
E Thervet, D Anglicheau, B King, MH Schlageter, B Cassinat, P Beaune, ...
Transplantation 76 (8), 1233-1235, 2003
3142003
Mutant debrisoquine hydroxylation genes in Parkinson's disease
M Armstrong, AK Daly, S Cholerton, JR Idle, DN Bateman
The Lancet 339 (8800), 1017-1018, 1992
3091992
The system can't perform the operation now. Try again later.
Articles 1–20